Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing.

Trial Profile

Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Oct 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Biomarker; Therapeutic Use
  • Acronyms INTASAH
  • Most Recent Events

    • 02 Oct 2016 New source identified and integrated (European Clinical Trials Database: EudraCT2009-018085-35)
    • 16 Nov 2014 The assessment duration of primary endpoint changed from 1 year (12 months) to 52 weeks (13 months), according to ClinicalTrials.gov record.
    • 16 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top